<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1233">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05145101</url>
  </required_header>
  <id_info>
    <org_study_id>W20_197#20.228</org_study_id>
    <nct_id>NCT05145101</nct_id>
  </id_info>
  <brief_title>Pneumococcal Vaccinatin in Patients With Chronic Lymphocytic Leukaemia</brief_title>
  <acronym>Pneumo-CLL</acronym>
  <official_title>Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Chronic Lymphocytic Leukaemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannah Garcia Garrido</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the antibody response after vaccination with the 13-valent pneumococcal&#xD;
      conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine&#xD;
      (PPSV23) in adults with chronic lymphocytic leukemia will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Patients with chronic lymphocytic leukaemia (CLL) are at increased risk of both&#xD;
      invasive pneumococcal disease (IPD) and community acquired pneumonia (CAP) caused by&#xD;
      Streptococcus pneumoniae. Therefore, international guidelines recommend pneumococcal&#xD;
      vaccination for all CLL patients, preferably before initiation of treatment. The recommended&#xD;
      vaccination schedule consists of Prevenar13®, a 13-valent pneumococcal conjugated vaccine&#xD;
      (PCV13) followed 2 months later by Pneumovax23, a 23-valent polysaccharide vaccine (PPSV23).&#xD;
&#xD;
      The immunological efficacy of this sequential vaccination schedule in CLL patients is&#xD;
      unknown. Previous studies have only investigated responses to either PCV13 or PPSV23 alone.&#xD;
      Responses to PPSV23 alone are poor in CLL patients. Responses to the 7-valent pneumococcal&#xD;
      conjugated vaccine (PCV7) or PCV13 are higher compared to responses to PPSV23, but lower&#xD;
      compared to responses in healthy individuals. More advanced disease stage and lower baseline&#xD;
      IgG negatively influence responses to vaccination.&#xD;
&#xD;
      The aim of this observational cohort study is to assess the immunogenicity of the currently&#xD;
      recommended vaccination schedule of PCV13 followed by PPSV23 in CLL patients.&#xD;
&#xD;
      2. Methods Study design and population As part of routine care, all adult CLL patients naïve&#xD;
      to pneumococcal vaccination and cared for in the Amsterdam UMC-location AMC, Flevoziekenhuis,&#xD;
      HagaZiekenhuis, Elisabeth-TweeSteden Hospital, Noordwest Ziekenhuisgroep, Albert Schweitzer&#xD;
      Hospital and Ikazia Hospital receive one dose of Prevenar13® followed by one dose of&#xD;
      Pneumovax23® 2 months later. According to the current local standard of care for&#xD;
      immunosuppressed individuals, the response to vaccination will be assessed by measuring&#xD;
      pneumococcal antibody levels before and 4-8 weeks after vaccination.&#xD;
&#xD;
      After obtaining informed consent clinical data will be collected by a trained medical&#xD;
      student, nurse or research assistant according to a standardized electronic case report form&#xD;
      (Castor EDC). Variables included in the case report form are: age, sex, smoking behaviour,&#xD;
      Rai stage (I/II/III), past or ongoing chemotherapy, ongoing steroid treatment, past or&#xD;
      ongoing therapy with a monoclonal anti-CD20 antibody (and date of last infusion), baseline&#xD;
      total IgG level, baseline lymphocyte count, baseline haemoglobin level, baseline platelet&#xD;
      level, baseline pneumococcal IgG levels, post-vaccination pneumococcal IgG levels, date of&#xD;
      PCV and PPSV23 vaccine administration, date of antibody measurements, comorbidities (Charlson&#xD;
      comorbitiy index).&#xD;
&#xD;
      Laboratory methods and definitions Serotype-specific pneumococcal immunoglobulin G (IgG)&#xD;
      concentrations to 5 pneumococcal serotypes shared across both vaccines (6B, 9V, 14, 19F, 23F)&#xD;
      and 4 serotypes unique to PPSV23 (8, 15B, 20, 33F) will be determined in the immunology&#xD;
      laboratory of the UMC Utrecht. A validated multiplex immunoassay will be used (Luminex®&#xD;
      technology). Serologic response will be defined as a ≥4-fold increase in serotype specific&#xD;
      anti-pneumococcal IgG for ≥70% of measured. Serologic protection will be defined as an&#xD;
      antibody concentration ≥1.3 mcg/ml for ≥70% of all measured serotypes, according to the&#xD;
      definition of the American Academy of Allergy, Asthma &amp; Immunology. In addition, because most&#xD;
      previous studies used the WHO cut-off for protection in infants (≥0.35mcg/ml) data will also&#xD;
      be analyzed by the infant correlate of protection to be able to compare the results with&#xD;
      previous studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serologic response rate</measure>
    <time_frame>1-2 months after vaccination schedule</time_frame>
    <description>Proportion of participants with a ≥4-fold increase in serotype specific anti-pneumococcal IgG for ≥6/9 serotypes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serologic protection rate</measure>
    <time_frame>1-2 months after vaccination</time_frame>
    <description>Antibody concentration ≥1.3 mcg/ml for ≥6/9 serotypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean concentrations of serotype specific anti-pneumococcal IgG for 9 pneumococcal serotypes</measure>
    <time_frame>Month 0, month 4</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pneumococcal Infections</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Vaccine-Preventable Diseases</condition>
  <condition>Invasive Pneumococcal Disease, Recurrent Isolated</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar13</intervention_name>
    <description>Patients receive one dose of Prevenar13 followed by one dose of Pneumovax23 2 months later</description>
    <other_name>Pneumovax23</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        As part of routine care, all adult CLL patients naïve to pneumococcal vaccination must&#xD;
        receive one dose of Prevenar13® followed by one dose of Pneumovax23® 2 months later.&#xD;
        According to the current local standard of care for immunosuppressed individuals, the&#xD;
        response to vaccination will be assessed by measuring pneumococcal antibody levels before&#xD;
        and 4-8 weeks after vaccination&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CLL&#xD;
&#xD;
          -  Age &gt;17&#xD;
&#xD;
          -  Naive to pneumococcal vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not able/willing to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Hannah Garcia Garrido, MD</last_name>
    <phone>+31205663800</phone>
    <email>h.m.garciagarrido@amsterdamumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amsterdam UMC Locatie AMC</name>
      <address>
        <city>Amsterdam-Zuidoost</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Garcia Garrido, MD</last_name>
      <phone>0031205663800</phone>
      <email>h.m.garciagarrido@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Koen de Heer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Hannah Garcia Garrido</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Vaccine-Preventable Diseases</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT05145101/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

